Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lijuan Fang

Showing results (61-70 of 62) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 62 results.
Journal of Medicinal Chemistry|June 4, 2011
Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profileHaishan Wang, Niefang Yu, Dizhong Chen, et al.
Schizophrenia Research|March 28, 2024
Tobacco smoking and nicotine vaping in persons with first episode psychosisMelanie E Bennett, Deborah Medoff, Tovah Cowan, et al.
Pageof 7

Showing results (61-70 of 62) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 62 results.
Journal of Medicinal Chemistry|June 4, 2011
Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profileHaishan Wang, Niefang Yu, Dizhong Chen, et al.
Schizophrenia Research|March 28, 2024
Tobacco smoking and nicotine vaping in persons with first episode psychosisMelanie E Bennett, Deborah Medoff, Tovah Cowan, et al.
Pageof 7